Viglimet™
Vildagliptin and Metformin HCl

COMPOSITION
Viglimet™ 50/850 Tablet: Each film-coated tablet contains Vildagliptin INN 50 mg and Metformin HCl BP 850 mg.
Viglimet™ 50/500 Tablet: Each film-coated tablet contains Vildagliptin INN 50 mg and Metformin HCl BP 500 mg.

PHARMACOLOGY
Viglimet™ combines two antidiabetic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin HCl, a member of the biguanide class.

DPP-4 is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinoctropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production.

By increasing and prolonging active incretin levels, Vildagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.

The pharmacologic mechanism of action of Metformin is different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization.

INDICATION
Viglimet™ is indicated in patients with type 2 diabetes who are unable to achieve sufficient glycemic control at their currently tolerated dose of oral Metformin alone or who are already treated with the combination of Vildagliptin and Metformin as separate tablets.

DOSE AND ADMINISTRATION
Adults: Based on the patient's current dose of Metformin, Combination of Vildagliptin & Metformin may be initiated at either 50 mg/500 mg or 50 mg/850 mg twice daily, 1 tab in the morning and the other in the evening. The recommended daily dose is 100 mg Vildagliptin plus 2000 mg Metformin HCl. Patients receiving Vildagliptin and Metformin from separate tablets may be switched to Combination of Vildagliptin & Metformin containing the same doses of each component. Doses higher than 100 mg of Vildagliptin are not recommended. There is no clinical experience of Viglimet and Metformin in triple combination with other antidiabetic agents. Taking Combination of Vildagliptin & Metformin in or just after food may reduce gastrointestinal symptoms associated with Metformin.

PRECAUTIONS
Lactic acidosis can occur due to Metformin accumulation. If metabolic acidosis is suspected, treatment should be discontinued and the patient should be hospitalized immediately. Serum creatinine should be monitored at least once a year in patients with normal renal function and 2-4 times a year in patients with serum creatinine levels at the upper limit of normal and in elderly patients. Special caution should be exercised in elderly patients where renal function may become impaired (e.g. when initiating antihypertensives, diuretics or NSAIDs). It is recommended that Liver Function Tests (LFTs) are monitored prior to initiation of this drug, at three-monthly intervals in the first year and periodically thereafter. If transaminase levels are increased, patients should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality return to normal. If AST or ALT persist at 3 x ULN, Vildagliptin & Metformin tablets should be stopped. Patients who develop jaundice or other signs of liver dysfunction. Following withdrawal of treatment with Vildagliptin & Metformin and LFT normalization, treatment with Vildagliptin & Metformin should not be reintroduced. Vildagliptin & Metformin tablets should be discontinued 48 hours before elective surgery with general anaesthesia and should not usually be resumed earlier than 48 hours afterwards.

CONTRAINDICATIONS
Combination (Vildagliptin & Metformin HCl) is contraindicated in patients with:
- Hypersensitivity to the active substance or to any of the excipients
- Patients with renal impairment: Creatinine clearance <60 mL/min.
- Patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
- Diabetic ketoacidosis should be treated with insulin
- Patients with type 1 diabetes

ADVERSE EFFECTS
The majority of adverse reactions were mild and transient, not requiring treatment discontinuations.

Lactic acidosis can occur due to Metformin. Rare cases of hepatic dysfunction. Some common side effects include tremor, headache, dizziness, nausea, hypoglycaemia, fatigue are seen. Clinical trials of up to and more than 2 years’ duration did not show any additional safety signals or unforeseen risks when use this combination.

DRUG INTERACTION
In pharmacokinetic studies, no interactions were seen with pioglitazone, metformin, glibenclamide, digoxin, warfarin, amiodipine, ramipril, valsalan or simvastatin. As with other oral antidiabetic medicinal products the glucose-lowering effect of Vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics. Close monitoring of glycemic control is required, when cationic drugs are co-administered. Glucocorticoids, beta-2 agonists, diuretics and ACE inhibitors may alter blood glucose. The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment. If necessary, the dosage of Vildagliptin & Metformin tablets may need to be adjusted during concurrent therapy and on its discontinuation.

USE IN PREGNANCY & LACTATION
PREGNANCY: There are no adequate data on the use of Vildagliptin & Metformin in pregnant women, hence the potential risk for human is unknown.

NURSING MOTHERS: It is not known whether Vildagliptin is excreted in human milk. Due to lack of human data, Vildagliptin & Metformin should not be used during lactation.

PEDIATRIC USE: Combination of Vildagliptin & Metformin is not recommended in patients 18 years of age.

GERIATRIC USE: Elderly (>65 years): As Metformin is renally excreted via the kidney, and elderly patients have a tendency its decreased renal function, elderly patients taking Combination of Vildagliptin & Metformin should have their renal function monitored regularly. Combination of Vildagliptin & Metformin has not been studied in patients >75 years. Therefore, the use of Combination of Vildagliptin & Metformin is not recommended in this population.

STORAGE
Store in a cool and dry place, protected from light and moisture. Keep out of the reach of children.

HOW SUPPLIED
Viglimet™ 50/500 Tablet: Each box contains 20 tablets in blister pack.
Viglimet™ 50/850 Tablet: Each box contains 20 tablets in blister pack.

Manufactured by:

SQUARE PHARMACEUTICALS LTD. BANGLADESH

TM - Trade Mark